T regulatory cells as an immunotherapy for transplantation

Expert Opinion on Biological Therapy

Volumn 6, Issue 4, 2006, Pages 315-324

  Albert, Michael H ^b   Anasetti, Claudio ^a   Yu, Xue Zhong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Graft versus host disease; Immunotherapy; Regulatory T cells; Transplantation

Indexed keywords

CYCLOSPORIN A; MONOCLONAL ANTIBODY; RAPAMYCIN; TSUKUBAENOLIDE;

ANTIGEN SPECIFICITY; CD4+ CD25+ T LYMPHOCYTE; DRUG EFFECT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; T-LYMPHOCYTES, REGULATORY;

EID: 33645791830     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.4.315     Document Type: Review

References (100)

1. YU X, CARPENTER P, ANASETTI C: Advances in transplantation tolerance. Lancet (2001) 357(9272):1959-1963.
2. WOOD KJ, SAKAGUCHI S: Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. (2003) 3(3):199-210.
3. SAKAGUCHI S, SAKAGUCHI N, SHIMIZU J et al.: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. (2001) 182:18-32.
4. TAKAHASHI T, KUNIYASU Y, TODA M et al.: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. (1998) 10(12):1969-1980.
5. LECHLER RI, GARDEN OA, TURKA LA: The complementary roles of deletion and regulation in transplantation tolerance. Nat. Rev. Immunol. (2003) 3(2):147-158.
6. ALBERT MH, YU XZ, MARTIN PJ, ANASETTI C: Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood (2005) 105(3):1355-1361.
7. WELLS AD, LI XC, LI Y et al.: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. (1999) 5(11):1303-1307.
8. TAYLOR PA, PANOSKALTSIS-MORTARI A, FREEMAN GJ et al.: Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood (2005) 105(8):3372-3380.
9. TAYLOR PA, PANOSKALTSIS-MORTARI A, NOELLE RJ, BLAZAR BR: Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody. J. Immunol. (2000) 164(2):612-622.
10. YU XZ, MARTIN PJ, ANASETTI C: Role of CD28 in acute graft-versus-host disease. Blood (1998) 92(8):2963-2970.
11. BLAZAR BR, TAYLOR PA, PANOSKALTSIS-MORTARI A, SHARPE AH, VALLERA DA: Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. (1999) 162(11):6368-6377.
12. QIN S, COBBOLD SP, POPE H et al.: 'Infectious' transplantation tolerance. Science (1993) 259(5097):974-977.
13. YIN D, FATHMAN CG: CD4-positive suppressor cells block allotransplant rejection. J. Immunol. (1995) 154(12):6339-6345.
14. CHEN ZK, COBBOLD SP, WALDMANN H, METCALFE S: Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 62(9):1200-1206.
15. LIU Z, TUGULEA S, CORTESINI R, SUCIU-FOCA N: Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int. Immunol. (1998) 10(6):775-783.
16. CHANG CC, CIUBOTARIU R, MANAVALAN JS et al.: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. (2002) 3(3):237-243.
17. + T cells from normal mice results in the spontaneous development of various autoimmune diseases, indicating that naturally occurring Tregs have an important role in the maintenance of self-tolerance.
18. COHEN JL, TRENADO A, VASEY D, KLATZMANN D, SALOMON BL: CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. (2002) 196(3):401-406.
19. ITOH M, TAKAHASHI T, SAKAGUCHI N et al.: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. (1999) 162(9):5317-5326.
20. + T cell clone as a source of foxp3-induced Tregs, and showed that those Tregs effectively prevented GVHD only when the recipient was immunised with the specific antigen. This study provides a basis for the concept that the onset and potency of suppression by Tregs can be regulated.
21. HOFFMANN P, ERMANN J, EDINGER M, FATHMAN CG, STROBER S: Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. (2002) 196(3):389-399. One of a series of papers demonstrating protection from experimental GVHD by coadministration of Tregs.
22. GROUX H, O'GARRA A, BIGLER M et al.: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389(6652):737-742.
23. LEVINGS MK, SANGREGORIO R, GALBIATI F et al.: IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. (2001) 166(9):5530-5539.
24. WEINER HL: Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. (2001) 182:207-214.
25. ZHANG J, GAO JX, SALOJIN K et al.: Regulation of fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. J. Exp. Med. (2000) 191(6):1017-1030.
26. SEINO KI, FUKAO K, MURAMOTO K et al.: Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. USA (2001) 98(5):2577-2581.
27. SAKAGUCHI S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. (2005) 6(4):345-352.
28. KUNIYASU Y, TAKAHASHI T, ITOH M et al.: Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. (2000) 12(8):1145-1155.
29. DARRASSE-JEZE G, MARODON G, SALOMON BL, CATALA M, KLATZMANN D: Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood (2005) 105(12):4715-4721.
30. ASANO M, TODA M, SAKAGUCHI N, SAKAGUCHI S: Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. (1996) 184(2):387-396.
31. FONTENOT JD, RUDENSKY AY: A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. (2005) 6(4):331-337.
32. LIANG S, ALARD P, ZHAO Y et al.: Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. (2005) 201(1):127-137.
33. KRETSCHMER K, APOSTOLOU I, HAWIGER D et al.: Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. (2005) 6(12):1219-1227.
34. SUZUKI H, KUNDIG TM, FURLONGER C et al.: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 268(5216):1472-1476.
35. KRAMER S, SCHIMPL A, HUNIG T: Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J. Exp. Med. (1995) 182(6):1769-1776.
36. SETOGUCHI R, HORI S, TAKAHASHI T, SAKAGUCHI S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. (2005) 201(5):723-735.
37. D'CRUZ LM, KLEIN L: Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. (2005) 6(11):1152-1159.
38. FONTENOT JD, RASMUSSEN JP, GAVIN MA, RUDENSKY AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. (2005) 6(11):1142-1151. A clear demonstration that IL-2 is critically required for the homeostasis and survival, but not for the development, of Tregs.
39. TAI X, COWAN M, FEIGENBAUM L, SINGER A: CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin-2. Nat. Immunol. (2005) 6(2):152-162.
40. TANG Q, BODEN EK, HENRIKSEN KJ et al.: Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. (2004) 34(11):2996-3005.
41. SERRA P, AMRANI A, YAMANOUCHI J et al.: CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity (2003) 19(6):877-889.
42. SALOMON B, LENSCHOW DJ, RHEE L et al.: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 12(4):431-440.
43. HERMAN AE, FREEMAN GJ, MATHIS D, BENOIST C: CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. (2004) 199(11):1479-1489.
44. GHIRINGHELLI F, MENARD C, TERME M et al.: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. (2005) 202(8):1075-1085.
45. LIM HW, HILLSAMER P, BANHAM AH, KIM CH: Cutting edge: Direct suppression of B cells by CD4+ CD25+ regulatory T cells. J. Immunol. (2005) 175(7):4180-4183.
46. THORNTON AM, SHEVACH EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. (2000) 164(1):183-190.
47. SHIMIZU J, YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. (2002) 3(2):135-142.
48. TAKAHASHI T, TAGAMI T, YAMAZAKI S et al.: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen-4. J. Exp. Med. (2000) 192(2):303-310.
49. HORI S, NOMURA T, SAKAGUCHI S: Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057-1061.
50. FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. (2003) 4(4):330-336.
51. KHATTRI R, COX T, YASAYKO SA, RAMSDELL F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. (2003) 4(4):337-342. References [49-51] highlight Foxp3 as a central element of Treg development and function.
52. BENNETT CL, OCHS HD: IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr. Opin. Pediatr. (2001) 13(6):533-538.
53. THORNTON AM, SHEVACH EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. (1998) 188(2):287-296.
54. KINGSLEY CI, KARIM M, BUSHELL AR, WOOD KJ: CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. (2002) 168(3):1080-1086.
55. TANG Q, ADAMS JY, TOOLEY AJ et al.: Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. (2006) 7(1):83-92.
56. WALKER LS, CHODOS A, EGGENA M, DOOMS H, ABBAS AK: Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. (2003) 198(2):249-258.
57. HOFFMANN P, EDER R, KUNZ-SCHUGHART LA, ANDREESEN R, EDINGER M: Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood (2004) 104(3):895-903.
58. TANG Q, HENRIKSEN KJ, BI M et al.: In wire-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. (2004) 199(11):1455-1465. An important paper demonstrating the ability of antigen-specific Tregs to revert ongoing autoimmune disease.
59. BLUESTONE JA, ABBAS AK: Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. (2003) 3(3):253-257.
60. TARBELL KV, YAMAZAKI S, OLSON K, TOY P, STEINMAN RM: CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. (2004) 199(11):1467-1477.
61. RONCAROLO MG, LEVINGS MK, TRAVERSARI C: Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. (2001) 193(2):F5-F9.
62. HORWITZ DA, ZHENG SG, GRAY JD et al.: Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol. (2004) 16(2):135-143.
63. MARTIN PJ: Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J. Exp. Med. (1993) 178(2):703-712.
64. TAYLOR PA, LEES CJ, BLAZAR BR: The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 99(10):3493-3499.
65. ERMANN J, HOFFMANN P, EDINGER M et al.: Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood (2005) 105(5):2220-2226.
66. TAYLOR PA, PANOSKALTSIS-MORTARI A, SWEDIN JM et al.: L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 104(12):3804-3812.
67. WYSOCKI CA, JIANG Q, PANOSKALTSIS-MORTARI A et al.: Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 106(9):3300-3307.
68. JOFFRE O, GORSSE N, ROMAGNOLI P, HUDRISIER D, VAN MEERWIJK JP: Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood (2004) 103(11):4216-4221.
69. EDINGER M, HOFFMANN P, ERMANN J et al.: CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. (2003) 9(9):1144-1150.
70. JONES SC, MURPHY GF, KORNGOLD R: Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol. Blood Marrow Transplant. (2003) 9(4):243-256.
71. TRENADO A, CHARLOTTE F, FISSON S et al.: Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. (2003) 112(11):1688-1696. References [69-71] report elegantly that administration of Tregs allows sufficient graft-versus-tumour activity while preventing GVHD.
72. MIURA Y, THOBURN CJ, BRIGHT EC et al.: Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 104(7):2187-2193.
73. ZORN E, KIM HT, LEE SJ et al.: Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 106(8):2903-2911.
74. RIEGER K, LODDENKEMPER C, MAUL J et al.: Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood (2006) 107(4):1717-1723.
75. CLARK FJ, GREGG R, PIPER K et al.: Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood (2004) 103(6):2410-2416.
76. BLUESTONE JA: Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. (2005) 5(4):343-349. A comprehensive review focusing on possible clinical application of Tregs.
77. LEONG LY, QIN S, COBBOLD SP, WALDMANN H: Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression. Eur. J. Immunol. (1992) 22(11):2825-2830.
78. SYKES M, SACHS DH: Bone marrow transplantation as a means of inducing tolerance. Semin. Immunol. (1990) 2(6):401-417.
79. HARA M, KINGSLEY CI, NIIMI M et al.: IL-10is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. (2001) 166(6):3789-3796.
80. GRACA L, COBBOLD SP, WALDMANN H: Identification of regulatory T cells in tolerated allografts. J. Exp. Med. (2002) 195(12):1641-1646.
81. ZHENG XX, SANCHEZ-FUEYO A, SHO M et al.: Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity (2003) 19(4):503-514.
82. SCHENK S, KISH DD, HE C et al.: Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J. Immunol. (2005) 174(6):3741-3748.
83. YOSHIZAWA A, ITO A, LI Y et al.: The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant. Proc. (2005) 37(1):37-39.
84. MELONI F, VITULO P, BIANCO AM et al.: Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation (2004) 77(5):762-766.
85. KARIM M, FENG G, WOOD KJ, BUSHELL AR: CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood (2005) 105(12):4871-4877. An important paper showing the importance of antigen-specific activation of Tregs in an allograft model in vivo.
86. GRACA L, LE MOINE A, LIN CY et al.: Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells. Proc. Natl. Acad. Sci. USA (2004) 101(27):10122-10126.
87. SANCHEZ-FUEYO A, SANDNER S, HABICHT A et al.: Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J. Immunol. (2006) 176(1):329-334.
88. BUSHELL A, JONES E, GALLIMORE A, WOOD K: The generation of CD25+ CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J. Immunol. (2005) 174(6):3290-3297.
89. CHAI JG, XUE SA, COE D et al.: Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation (2005) 79(10):1310-1316.
90. LI XC, STROM TB, TURKA LA, WELLS AD: T cell death and transplantation tolerance. Immunity (2001) 14(4):407-416.
91. KAWAI M, KITADE H, MATHIEU C, WAER M, PIRENNE J: Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation (2005) 79(9):1073-1077.
92. COENEN JJ, KOENEN HJ, RIJSSEN EV, HILBRANDS LB, JOOSTEN I: Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood (2005) 107(3):1018-1023.
93. BATTAGLIA M, STABILINI A, RONCAROLO MG: Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 105(12):4743-4748. A paper describing one of several innovative methods to expand Tregs ex vivo.
94. GAME DS, HERNANDEZ-FUENTES MP, LECHLER RI: Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am. J. Transplant. (2005) 5(3):454-464.
95. GREGORI S, CASORATI M, AMUCHASTEGUI S et al.: Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. (2001) 167(4):1945-1953.
96. HEROLD KC, HAGOPIAN W, AUGER JA et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. (2002) 346(22):1692-1698. A clinical study showing that anti-CD3 therapy has the potential to control the progression of diabetes, at least partially, by promoting immunoregulation.
97. CARPENTER PA, APPELBAUM FR, COREY L et al.: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 99(8):2712-2719.
98. OPELZ G: Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study. Transplant. Proc. (1997) 29(1-2):617-619.
99. KOHM AP, WILLIAMS JS, BICKFORD AL et al.: Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. (2005) 174(8):4525-4534.
100. KESSELS HW, WOLKERS MC, VAN DEN BOOM MD, VAN DER VALK MA, SCHUMACHER TN: Immunotherapy through TCR gene transfer. Nat. Immunol. (2001) 2(10):957-961.